ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer

Immunotherapy with checkpoint inhibitors (CPI) targeting PD-1 or CTLA-4 has emerged as an important treatment modality for several cancer forms. In hormone receptor positive breast cancer (HR  + BC), this thera...

Source: Journal of Translational Medicine - July 3, 2020 Category: Research Authors: J. A. Kyte, N. K. Andresen, H. G. Russnes, S. Ø. Fretland, R. S. Falk, O. C. Lingjærde and B. Naume Tags: Protocol Source Type: research